Technology

Valor Medical has developed a new derivative of a cyanoacrylate monomer that will change (polymerize) from a liquid to a sponge like material when it comes in contact with blood. Valor Medical has six patents pending, two of which have had first office action. The company plans to aggressively pursue additional intellectual property that will have patent potential.

Valor Medical’s product, Neucrylate™ can be directly injected into a cerebral berry aneurysm once a microcatheter is placed. This procedure takes less surgical time, which will reduce the cost for the surgical procedure and reduce the time that the patient is under anesthesia. Neucrylate can fill the entire aneurysm (unlike coils, which rarely exceed 33% filling), and does not shrink when the liquid changes to a sponge like material (unlike other solvent based devices). These properties should eliminate the need for patients to be treated with coils, which sometimes shift or collapse, creating a pathway for blood and its pressures to enter the aneurysm, and thus needing to be retreated. Neucrylate may also be used for patients whose coils have failed. Such retreatment is often referred to as coil salvage therapy.

The first product, Neucrylate A™, is formulated to meet the delivery requirements for treating cerebral berry aneurysm and coil salvage therapy. A second product is being formulated to meet the behavioral requirements for treating AVMs. A third generation product will be formulated to meet the behavioral requirements for treating vascular brain tumors.